Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-04-2421PMID 16115903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.

  2005cited by this paper
• The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.

  2004cited by this paper
• Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  2004cited by this paper
• Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

  2004cited by this paper
• Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer.

  2004cited by this paper
• Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

  2003cited by this paper
• Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.

  2002cited by this paper
• Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000influential reference
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• [The female breast].

  1993cited by this paper
• Further observations on prognostic factors in cancer of the female breast

  1969cited by this paper

• Significance of MALAT1 long non-coding RNA and miR-20a-5p in regulating epithelial mesenchymal transition in luminal breast cancer patients

  2026cites this paper
• Pathological response to neoadjuvant chemotherapy and survival in patients with breast cancer: A multicentric retrospective study

  2026cites this paper
• Poly-ε-caprolactone nanoparticles in breast cancer therapy: bridging bench research and clinical potential.

  2026cites this paper
• Hallmarks of cancer in canine mammary tumors: Insights into a potential model for human triple-negative breast cancer.

  2026cites this paper
• Anti‐Proliferative and Apoptotic Evaluation of a Novel Synthesized Acridine Hybrid With Anticipated Synergistic Effect to Paclitaxel on Breast Cancer Cells

  2026cites this paper
• Applications of Metabolomics to the Clinical Management of Breast Cancer: New Perspectives for Diagnosis, Treatment and Prognosis

  2026cites this paper
• Design and Development of Optimised Nanostructured Polymeric Systems of Raloxifene For Improved Biopharmaceutical Application in Breast Cancer: A Review

  2025cites this paper
• Androgen receptor expression in triple negative breast cancer: an Algerian population study

  2025cites this paper
• Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria

  2025cites this paper
• Assessing the Efficacy of Current Histopathological Tumor Reporting Systems for Evaluating the Response to Neoadjuvant Chemotherapy for Breast Carcinoma: Protocol for an Observational Study

  2025cites this paper
• The Effect of Positron Emission Tomography-Computed Tomography Parameters on Pathological Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Treatment

  2025cites this paper
• Role of Glucocorticoid Receptor in Triple-Negative Breast Cancer

  2025cites this paper
• Enhanced ETS1 stability by DNAPKcs orchestrates transcriptional changes during chemoresistance in triple negative breast cancer

  2025cites this paper
• Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor‐Microenvironment‐on‐a‐Chip

  2025cites this paper
• Advances in iron oxide nanoparticles for targeted breast cancer therapy: a promising nanomedicine approach

  2025cites this paper
• Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications

  2025cites this paper
• Aurora Kinase A: The Prominent Oncogenic Link in Helicobacter pylori‐Driven Gastric Carcinogenesis

  2025cites this paper
• Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  2025cites this paper
• Decoding the adaptive survival mechanisms of breast cancer dormancy

  2025cites this paper
• Comparing irradiated clinical outcomes between modified radical mastectomy and breast-conserving surgery in patients with pathologic stage III breast cancer: A national population-based match cohort study.

  2025cites this paper
• Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

  2025cites this paper
• The histone acetyltransferase CBP participates in regulating the DNA damage response through ATM after double-strand breaks

  2025cites this paper
• Fusion model integrating multi-sequence MRI radiomics and habitat imaging for predicting pathological complete response in breast cancer treated with neoadjuvant therapy

  2025cites this paper
• The BMP4-BMPR1A axis represses BRCA1 in mammary stem cells and contributes to tumor initiation

  2025cites this paper
• Integrative Radiogenomics Using MRI Radiomics and Microarray Gene Expression Analysis to Predict Pathological Complete Response in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

  2025cites this paper
• Subtyping Social Determinants of Health in the "All of Us" Program: Network Analysis and Visualization Study

  2025cites this paper
• Long-term survival outcomes of neoadjuvant chemotherapy in stage II-III HR+/HER2- breast cancer

  2025cites this paper
• Systems biology successes and areas for opportunity in prostate cancer

  2025cites this paper
• A Study of Correlation of Expression of Er, Pr & Her2neu Receptor Status with the Clinico-pathological Prognostic Factor in Breast Carcinoma

  2025cites this paper
• Prognostic Interplay of Caveolin1 and FOXC1 in Early Nonmetastatic Triple Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

  2025cites this paper
• Integrated transcriptome study reveals a stress response state CD4 +T cells related to immune tolerance in breast cancer

  2025cites this paper
• Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer

  2025cites this paper
• Engineering Complex Breast Tumor-Stroma Models: TMPyP4-Photodynamic Therapy Is More Effective at the Metastatic Site in Breast Tumors

  2025cites this paper
• The Influence of AQP5 on the Response to Hydrogen Peroxide in Breast Cancer Cell Lines

  2025cites this paper
• Exploring Breast Cancer-Associated Genes: A Comprehensive Analysis and Competitive Endogenous RNA Network Construction.

  2025cites this paper
• Clinical Implications of Breast Cancer Intrinsic Subtypes.

  2025cites this paper
• Optimizing Triple-Negative Breast Cancer Therapy via Ultrasound-Enhanced Piezocatalysis for Targeted Chemodrug Release

  2025cites this paper
• The Autophagy Inhibitor Bafilomycin Inhibits Antibody-Dependent Natural Killer Cell-Mediated Killing of Breast Carcinoma Cells

  2025cites this paper
• Recent Prospectives of Cellular Signaling Role for Mammary Gland Carcinogenesis.

  2025cites this paper
• Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?

  2024cites this paper
• Exploring novel protein-based biomarkers for advancing breast cancer diagnosis: A review.

  2024cites this paper
• Investigation of efficacy of two different chemotherapy protocols used in neoadjuvant chemotherapy in clinical stages II-IV canine malignant mammary tumours.

  2024cites this paper
• A Deep Learning Model for Predicting Molecular Subtype of Breast Cancer by Fusing Multiple Sequences of DCE-MRI From Two Institutes.

  2024cites this paper
• Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction

  2024cites this paper
• Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy.

  2024cites this paper
• Plant-based natural products in cancer therapeutics

  2024cites this paper
• Breast cancer and laser therapy

  2024cites this paper
• Liquid biopsy for breast cancer and other solid tumors: a review of recent advances

  2024cites this paper
• A Molecular Typing Method for Invasive Breast Cancer by Serum Raman Spectroscopy.

  2024cites this paper
• Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.

  2024cites this paper
• Prognostic Value of “Basal-like” Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer

  2024cites this paper
• The Difference of RCB 0 and RCB I in Prognosis of Breast Cancer After Neoadjuvant Therapy: A Meta-Analysis.

  2024cites this paper
• Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer

  2024cites this paper
• Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

  2024cites this paper
• Fabrication, Characterization and Evaluation of Gallic Acid-Encapsulated Curdlan Gum Nanoparticles with Potential Application for Breast Cancer Treatment

  2024cites this paper
• Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets

  2024cites this paper
• Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer

  2024cites this paper
• Knockdown of Keratin 6 Within Arsenite-Transformed Human Urothelial Cells Decreases Basal/Squamous Expression, Inhibits Growth, and Increases Cisplatin Sensitivity

  2024cites this paper
• Multifaceted role of phytoconstituents based nano drug delivery systems in combating TNBC: A paradigm shift from chemical to natural

  2024cites this paper
• Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer

  2024cites this paper
• A New Benzo[6,7]oxepino[3,2-b] Pyridine Derivative Induces Apoptosis in Canine Mammary Cancer Cell Lines

  2024cites this paper
• A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study

  2024cites this paper
• Identifying radiogenomic associations of breast cancer based on DCE‐MRI by using Siamese Neural Network with manufacturer bias normalization

  2024cites this paper
• Public neoantigens in breast cancer immunotherapy (Review)

  2024cites this paper
• Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple‐negative breast cancer

  2024cites this paper
• Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016)

  2024cites this paper
• Targeting overexpressed surface proteins: A new strategy to manage the recalcitrant triple-negative breast cancer.

  2024cites this paper
• Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review

  2024cites this paper
• CORONet: A Cross-Sequence Joint Representation and Hypergraph Convolutional Network for Classifying Molecular Subtypes of Breast Cancer Using Incomplete DCE-MRI

  2024cites this paper
• GSDME-mediated pyroptosis promotes anti-tumor immunity of neoadjuvant chemotherapy in breast cancer

  2024cites this paper
• Organoid models of breast cancer in precision medicine and translational research

  2024cites this paper
• Assessing the Role of Different Heterogeneous Regions in DCE-MRI for Predicting Molecular Subtypes of Breast Cancer based on Network Architecture Search and Vision Transformer

  2023cites this paper
• Triple Negative Breast Cancers: An Obsolete Entity?

  2023cites this paper
• Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study

  2023cites this paper
• Bone-homing metastatic breast cancer cells impair osteocytes’ mechanoresponse in a 3D loading model

  2023cites this paper
• Rank-based Bayesian clustering via covariate-informed Mallows mixtures

  2023cites this paper
• A case report and literature review on a rare subtype of triple-negative breast cancer in children

  2023cites this paper
• Clinical application and pharmacological mechanism of polyherbal phytoformulations in breast cancer and depression treatment: review and network pharmacological analysis

  2023cites this paper
• Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment

  2023cites this paper
• Stromal Tumor-Infiltrating Lymphocytes Associated with Immunohistopathology and Molecular Subtypes of Breast Cancer in Vietnam

  2023cites this paper
• Pathological response of different molecular subtypes of locally advanced breast carcinoma to neoadjuvant chemotherapy

  2023cites this paper
• Unraveling patient heterogeneity in complex diseases through individualized co-expression networks: a perspective

  2023cites this paper
• Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer

  2023cites this paper
• Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

  2023cites this paper
• Common hotspots of cancer chemotherapy

  2023cites this paper
• Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC

  2023cites this paper
• Comparative assessment of breast cancer prevalence between women in Saudi Arabia and Egypt

  2023cites this paper
• Antiproliferative Activity and Mechanisms of Action of Plant-Derived Flavonoids on Breast Cancer.

  2023cites this paper
• Multi-study R-learner for estimating heterogeneous treatment effects across studies using statistical machine learning

  2023cites this paper
• Effects of Cortactin Expression on Prognosis in Patients with Breast Cancer

  2023cites this paper
• Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer

  2023cites this paper
• Synthesis, and In-silico Studies of Indole-chalcone Derivatives Targeting Estrogen Receptor Alpha (ER-α) for Breast Cancer.

  2023cites this paper
• Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study

  2023cites this paper
• Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.

  2023cites this paper
• Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

  2023cites this paper
• SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches

  2023cites this paper
• In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets

  2023cites this paper
• Deciphering breast cancer: from biology to the clinic.

  2023cites this paper
• Inhibition of ERK signaling for treatment of ERRα positive TNBC

  2023cites this paper
• Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook

  2023cites this paper